Reply To: Avacta

Nick Hargrave

This is an excellent update by Avacta. The key phrase is “several patients in cohort 5 and earlier cohorts remain on treatment as their disease has not progressed”. This is still a Phase 1a safety study, but this is first explicit confirmation from the company that AVA6000 is efficacious and is aiding patients who have not previously responded to treatment, without the usual chemo side effects